Articles on Making the Investment Case

Making the Case


     •     Research and development for neglected diseases: more is still needed, and faster. Utzinger J & Keiser J. The Lancet Global Health, Volume 1, Issue 6, Pages e317 - e318, December 2013

     •     The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment Articles/ PDP Related Reports Archives. Pedrique B et al. The Lancet Global Health, Volume 1, Issue 6, Pages e371 - e379, December 2013

     •     Sustaining the drive to overcome the global impact of neglected tropical diseases. WHO. 2013.

     •     Ending the R&D Crisis in Public Health: Promoting pro-poor medical innovation.  Oxfam Briefing Paper 122.

     •     Global burden and investment for neglected diseases? Dimitri N. The Lancet Infectious Diseases, Volume 10, Issue 10, Pages 658 - 660, October 2010

     •     Neglected disease research and development: New times, new trends.  George Institute.  December 2009


     •     G-Finder Factsheet: Diagnostic R&D for neglected diseases. Policy Cures. November 2013.

     •     Bringing the lab to the patient: developing point-of-care diagnostics for resource limited settings. A report from the American Academy of Microbiology.  2012.

     •     The Diagnostics Innovation Map: Medical Diagnostics for the Unmet Needs of the Developing World. BVGH. 2010.


     •     Ranking Vaccines: A Prioritization Software Tool - Phase II: Prototype of a Decision-Support System. Institute of Medicine (IOM). September 2013

     •     Why Invest in Vaccines.  GAVI Website. October 2013

     •     Working Towards Affordable Pricing for HPV Vaccines for Developing Countries: The Role of GAVI. The Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries WORKING PAPER AND BACKGROUND NOTE SERIES, NO. 3.  September 2011.

     •     The Need for New Vaccines .pdf.  K Taylor et al.  Vaccine 27S(2009) G3-G8.

     •     The Value of Vaccines.  Two centuries of unparalleled medical progress.  IFPMA. May 2008


     •     Global strategy for dengue prevention and control 2010-2020. WHO. 2012

     •     The global distribution and burden of dengue. Bhatt S et al. Nature (2013) doi:10.1038/nature12060 Published online 07 April 2013

     •     Cost-effectiveness of a pediatric dengue vaccine. Schneider Institute for Health Policy, Brandeis University. September 2003

HIV Prevention

     •     An Action Agenda to End AIDS.  Where are we in realizing the promise of beginning to end AIDS.  amfAR & AVAC. September 2013.

     •     Combination HIV Prevention: Tailoring and Coordinating Biomedical, Behavioural and Structural Strategies to Reduce New HIV Infections. UNAIDS. November 2011.

     •     A new investment framework for the global HIV response. UNAIDS.  October 2001.

     •     Where does public funding for HIV prevention go to? The case of condoms versus microbicides and vaccines. Peters AJTP et al. Globalization and Health. 30 December 2010; 6:23.


     •     Microbicides:  Ways Forward 2010.  Stone A and Harrison PF. Alliance for Microbicide Development Report.  May 2010.

     •     Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Verguet S and J A Walsh JA.  Sexually Transmitted Infections. 1 June 2010; 86(3):212-216.

     •     Scenario planning for 1% tenofovir gel. Prepared by the Boston Consulting Group. January 2011. Steering Committee 110124 vSENT.pdf

     •     USAID Microbicide Report 2011.  USAID Shared vision and strategic plan for microbicide introduction draft 7 5 11.docx

     •     Capitalizing on Success: Investment in HIV Prevention R&D in 2010.  HIV Vaccines and Microbicides Resource Tracking Working Group.  July 2011.

     •     The Economics of Microbicide Development: A Case for Investment. The Rockefeller Foundation's Microbicide Initiative Pharmaco-Economics Working Group. 2001


     •     Modeling HIV Vaccines in Brazil: Assessing the Impact of a Future HIV Vaccine on Reducing New Infections, Mortality and Number of People Receiving ARV.  Goretti M et al. PLoS ONE 5(7): e11736. doi:10.1371/journal.pone.0011736. July 2010.

     •     Global HIV Vaccine Enterprise.  The Road to Prevention: A special preview of the Global HIV Vaccine Enterprise 2010 Scientific Strategic Plan.  July 18. 2010.


     •     From Pipeline to Product: Malaria R&D Funding Needs into the Next Decade. PATH. December 2013.

     •     Business Investing in Malaria Control: Economic Returns and a Healthy Workforce for Africa. Roll Back Malaria. May 2011

     •     Malaria in Africa Can Be Eliminated. Campbell CC and Steketee RW.  Am J Trop Med Hyg 2011 vol. 85 no. 4 584-585

     •     T3: Test. Treat. Track: Scaling up diagnostic testing, treatment and surveillance for malaria. WHO. June 2012

     •     The malaria product pipeline: planning for the future.  The George Institute for International Health.  2007.

     •     Malaria Vaccine Decision-Making Project.  Project Website.


     •     Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities. Birkett AJ et al. Vaccine Volume 31, Supplement 2. Pages: B233-B243

     •     Modeling the public health impact of malaria vaccines for developers and policymakers. Nunes JK et al. BMC Infectious Diseases 2013, 13:295

     •     Malaria Vaccine Initiative with the Boston Consulting Group. January 2005

Other neglected diseases

     •     A research agenda for helminth diseases of humans: diagnostics for control and elimination programmes. McCarthy JS et al. PLoS Negl Trop Dis 6(4): e1601. doi:10.1371/journal.pntd.0001601

     •     The Human Hookworm Vaccine. Hotez PJ et al. Vaccine Volume 31, Supplement 2. Pages: B227-B232

     •     Case study for a vaccine against leishmaniasis. Alvar J et al. Vaccine Volume 31, Supplement 2. Pages: B244-B249

     •     Global economic burden of Chagas disease: a computational simulation model. Lee BL et al. The Lancet Infectious Diseases, Volume 13, Issue 4, Pages 342 - 348, April 2013

     •     Do we need new drugs against human African trypanosomiasis? Stich A et al. The Lancet Infectious Diseases, Volume 13, Issue 9, Pages 733 - 734, September 2013

     •     G-Finder Factsheet:  R&D for diarrhoeal diseases. Policy Cures. November 2013.

     •     Research priorities for Chagas disease, human African trypanosomiasis and Leishmaniasis. WHO Technical Report Series. 2012.


     •     WHO Global Tuberculosis Report 2013

     •     Priorities for tuberculosis research: a systematic review. Rylance J et al. The Lancet Infectious Diseases, Volume 10, Issue 12, Pages 886 - 892, December 2010

     •     A rational vaccine pipeline for tuberculosis. Brennan MJ et al. The International Journal of Tuberculosis and lung disease. Volume 16, Number 12, 1 December 2012

     •     TB R & D Report 2005-2010 - 2nd Edition. Treatment Action Group and Stop TB Partnership. March 2012.

     •     Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.  Wallis RS et al. The Lancet. May 29, 2010. 375 (9729): 1920-1937.

     •     Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action.  Atun R et al. The Lancet. June 19, 2010. 375 (9732): 2169-2178

     •     An international roadmap for tuberculosis research. Stop TB partnership and WHO.  October 2001.


     •     New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future. Lienhardt C. et al. Journal of Infectious Diseases Advance Access published March 23, 2012

     •     Global tuberculosis drug development pipeline: the need and the reality.  Ma Z et al. The Lancet. June 12, 2010. 375 (9731): 2100-2109.


     •     Tuberculosis vaccines: a strategic blueprint for the next decade. Brennan MJ & Thole J. Tuberculosis.  Vol: 92 Suppl 1(S6-S13). March 2012

     •     Rational approach to selection and clinical development of TB vaccine candidates.  Barker L et al. Tuberculosis.  Vol: 92 Suppl 1(S25-S29). March 2012

     •     Bridging the gap: Engaging researchers and advocates to build support for TB vaccine research and development.  Kennell M & Wooley J. Tuberculosis.  Vol: 92 Suppl 1(S30-S32). March 2012

     •     An urgent call for a stronger, louder voice for TB vaccine advocacy. Tameris M et al. Tuberculosis.  http://dx.doi.org/10.1016/j.tube.2013.02.016. Available online 14 March 2013.

     •     Preventive vaccines for tuberculosis. Evans TG et al. Vaccine Volume 31, Supplement 2. Pages: B223-B226

     •     New vaccines for tuberculosis. Kaufmann SHE et al. The Lancet. June 12, 2010. 375 (9731): 2110-2119.

     •     Tuberculosis Vaccines: The Case for Investment.  BIO Ventures for Global Health. October 2006

Collateral Benefits

     •     Capacity Building Matters: An overview of MMV's capacity building activities. MMV. September 2013

     •     Collateral Benefits: How the Pursuit of an AIDS Vaccine Has Boosted African Research.  Thomson H. Frontlines.  June/ July 2011.

PDP Related Materials


     •     Business Case for Investment in TB vaccines.  Aeras and TBVI. 2013

     •     The need for New TB Vaccines. Aeras 2012

     •     Economics of TB Vaccine Workshop. July 18-19, 2012. Summary Report. Aeras. August 2012.

Dengue Vaccine Initiative

     •     PDVI DenguEcon, an economic model of dengue vaccination.  January 2011.


     •     Developing new Diagnostic Tests for Human African Trypanosomiasis. Current Status and Future Plans. 2013.

     •     FIND Acute febrile syndrome strategy. 2012.

     •     FIND Malaria Strategy. FIND. 2012.

     •     Diagnostics for Tuberculosis:  Global Demand and Market Potential


     •     The potential impact of an AIDS Vaccine in low- and middle-income countries. IAVI Policy Brief 29  May 2012.

     •     AIDS Vaccines: Exploring the Potential Cost/ Benefit. IAVI Policy Brief 30. May 2012.

     •     Spotlight on Women: Modeling the impact of a future AIDS vaccine.  IAVI Policy Note. May 2012.

     •     China: Estimating the impact of an AIDS Vaccine.  IAVI. August 2012.

     •     AIDS Vaccine Blueprint 2008:  A challenge to the field, a roadmap for progress

     •     Forecasting Demand for Preventative HIV Vaccines in India.  International AIDS Vaccine Initiative. June 2007


     •     Why Microbicides for Women? 2013.

     •     Partnering to Advance Global Health: Advantages of the Product Development Partnership Model. 2011


     •     Saving Lives With Multipurpose Prevention Technologies: Turning Ideas Into Solutions for Sexual and Reproductive Health. Holt BY et al.  Coalition Advancing Multipurpose Innovations, PATH.  May 2010.

TB Alliance

     •     Pathway to Patients: Charting the Dynamics of the Global TB Drug Market. Global Alliance for TB Drug Development. May 2007

     •     TB Alliance - Interactive Portfolio TB Alliance. June 2013

     •     The Economics of TB Drug Development (2001)

Funder Related Material


     •     Donor Investment Choices: Modelling the value for money of investing in PD PPPs as compared to other health care and non-health care interventions.  Summary report.  Office of Health Economics (OHE).  November 2006.  Study commissioned by The Rockefeller Foundation.

     •     OHE Summary report 10.11.06.doc

     •     PDP Cost-Benefit.ppt

     •     Presentation in September 2006:  Donor investment choices for global health: modelling the value for money of investing in product development public private partnerships (PD PPPs)


     •     An Emerging Leader: Germany's Role in Neglected and Poverty-Related Disease R&D. Policy Cures. December 2013


     •     DFID Research Strategy 2008-2013

     •     DFID Research Strategy 2008-2013. Working Paper Series: Better Health

     •     Supporting the global AIDS vaccine R&D effort: the UK example.  Presentation by Sue Kinn of DFID to IAVI sponsored meeting in Berlin, November 2007. Berlin presentation for IAVI meeting - sue kinn.ppt


     •     USAID: Report to Congress:  Health-related research and development strategy. 2011-2015.  December 2012.

     •     Renewing US leadership: Policies to advance global health research.  Global Health Technologies Coalition (GHTC). February 2013.

     •     The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research. Institute of Medicine (IOM). June 2013

     •     Improving health at home and abroad.  How the US Food and Drug Administration can maximize its global impacts. GHTC. September 2013.